Comparison of the effects of pindolol and propranolol on exercise performance in patients with angina pectoris.
The effects of pindolol (mean dose 17 +/- 8 mg/day), a beta-blocking drug with intrinsic sympathomimetic activity (ISA), and propranolol (130 +/- 40 mg/day) on exercise performance in 11 patients with stable angina pectoris were compared. Doses were titrated to symptoms. The design was a randomized, double-blind, crossover protocol with 8 weeks of treatment with each drug. At the end of each drug period, subjects performed 3 exercise tests: a symptom-limited test on a cycle ergometer with measurement of gas exchange parameters; a steady-state exercise test to measure cardiac output by the CO2 rebreathing method; and a supine exercise test with radionuclide angiography. The ISA effect of pindolol was evident at rest in that the heart rate of 82 +/- 4 beats/min was higher than with propranolol (70 +/- 3). At low levels of exercise heart rate, cardiac output and O2 consumption (VO2) were still higher. However, there was no difference in cardiac output or VO2 at higher levels of exercise and no difference in the VO2 at the anaerobic threshold and peak exercise. Peak VO2 was 1,344 +/- 108 ml/min with propranolol and 1,350 +/- 116 with pindolol therapy. There were also no differences in ejection fraction or cardiac volumes at rest or during exercise. The incidence of side effects was similar with both drugs and there was no significant preference for either medication. In conclusion, patients with angina treated with pindolol had the same peak exercise performance as with an 8:1 equivalent dose of propranolol (clinically equivalent), although at lower levels of exercise, VO2, cardiac output and heart rate were higher from the ISA of pindolol.